Beta Bionics, Inc. (BBNX): Cost of Revenue

Annual figures by period end, from SEC filings.

$44.71M

Year ended 2025-12-31

$49.61M

Trailing 12 months to 2026-06-30

2023-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$44.71M	+52.9%	2026-02-24, From 2025-01-01
2024-12-31	$29.24M	+414.1%	2026-02-24, From 2024-01-01
2023-12-31	$5.69M	n/a	2025-03-28, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Beta Bionics, Inc. (BBNX)	2025-12-31	$44.71M	+52.9%
NeuroPace Inc (NPCE)	2025-12-31	$22.77M	+9.3%
Kestra Medical Technologies, Ltd. (KMTS)	2026-04-30	$46.26M	+29.9%
Pulmonx Corp (LUNG)	2025-12-31	$23.36M	+7.2%
Anika Therapeutics, Inc. (ANIK)	2025-12-31	$49.01M	+11.6%
Orasure Technologies Inc (OSUR)	2025-12-31	$66.82M	-37.2%
Delcath Systems, Inc. (DCTH)	2025-12-31	$11.80M	+90.6%
Iradimed Corp (IRMD)	2025-12-31	$19.49M	+15.4%
PRO DEX Inc (PDEX)	2026-06-30	$53.21M	+13.0%

Compare BBNX, NPCE, KMTS, LUNG side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗